摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Methylbenzyl pivalate | 83674-23-1

中文名称
——
中文别名
——
英文名称
3-Methylbenzyl pivalate
英文别名
(3-Methylphenyl)methyl 2,2-dimethylpropanoate
3-Methylbenzyl pivalate化学式
CAS
83674-23-1
化学式
C13H18O2
mdl
MFCD25969894
分子量
206.285
InChiKey
IISSLUMAZIHNOX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    268.6±9.0 °C(Predicted)
  • 密度:
    0.991±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.461
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-Methylbenzyl pivalate 以7%的产率得到
    参考文献:
    名称:
    Pincock J.A., Wedge P.J., J. Org. Chem., 59 (1994) N 19, 5587-5595
    摘要:
    DOI:
  • 作为产物:
    描述:
    3-甲基苄醇三甲基乙酰氯吡啶 作用下, 以 为溶剂, 生成 3-Methylbenzyl pivalate
    参考文献:
    名称:
    The Photochemistry of Methoxy-Substituted Benzyl Acetates and Benzyl Pivalates: Homolytic vs Heterolytic Cleavage
    摘要:
    The multiple methoxy-substituted benzyl acetates (3g-i) and benzyl pivalates (4g-i) have been photolyzed in methanol solution. The products of these reactions are derived from two critical intermediates; the benzyl radical/acyloxy radical pair and the benzyl cation/carboxylate anion pair. As predicted by the meta effect, the yield of ion-derived product, the methyl ether in this case, was enhanced by the presence of the m-methoxy groups. The yield of ether, for the acetate esters, varied from 2% for the 4-methoxy-substituted ester to 66% for the 3,4,5-trimethoxy-substituted ester. In contrast, the yield of ether, for the pivalate esters, varied from <1% for the 4-methoxy-substituted ester to 20% for the 3,4,5-trimethoxy-substituted one. The meta effect does not explain these differences; electron transfer converting the radical pair to the ion pair is still an important pathway in the mechanism for ion formation. A quantitative analysis of the yield of the ethers was done in order to obtain the electron-transfer rate constants. This analysis revealed that the yield of the ethers was higher than expected based on previous results for other substituted benzyl acetates. A possible explanation for this discrepancy is that internal return of the radical pair to starting material for the acetate esters is more efficient than for the pivalate esters. Also, the esters 3k and 3l, were prepared to study the effect of electron-withdrawing groups in the meta position. For these esters, the benzylic cleavage reactions were inefficient and an isomerization reaction, the benzvalene rearrangement, was competitive.
    DOI:
    10.1021/jo00098a016
点击查看最新优质反应信息

文献信息

  • Dual-acting benzoimidazole antihypertensive agents
    申请人:Allegretti Paul
    公开号:US20080318951A1
    公开(公告)日:2008-12-25
    The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R 2-3 and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    这项发明涉及具有以下结构的化合物: 其中:Ar、r、n、X、R 2-3 和R 5-7 如规范中所定义,并且其药学上可接受的盐。这些化合物具有AT 1 受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物;使用这些化合物的方法;以及制备这些化合物的过程和中间体。
  • Efficient Cross-Coupling Reactions of (Pivaloyloxymethyl)zinc Chloride
    作者:Paul Knochel、Romain Blanc、Klaus Groll、Sebastian Bernhardt、Paul Stockmann
    DOI:10.1055/s-0033-1340819
    日期:——
    Abstract (Pivaloyloxymethyl)zinc chloride, obtained by an iodine–magnesium exchange and subsequent transmetalation, shows a much higher reactivity in Negishi cross-couplings than the corresponding zinc organometallic, prepared by direct zinc insertion. Furthermore, a substituted derivative of (pivaloyloxymethyl)zinc chloride is prepared starting from pivaloyloxymethyl sulfoxide using TMPZnCl·LiCl (TMP
    摘要 通过碘-镁交换和随后的重金属化作用获得的(新戊酰氧基甲基)氯化锌比直接通过锌的插入制备的相应有机金属锌在Negishi交叉偶合中具有更高的反应活性。此外,使用TMPZnCl·LiCl(TMP = 2,2,6,6-四甲基哌啶基),从新戊酰氧基甲基亚砜开始,制备(新戊酰氧基甲基)氯化锌的取代衍生物,然后进行亚砜-镁交换。 通过碘-镁交换和随后的重金属化作用获得的(新戊酰氧基甲基)氯化锌比直接通过锌的插入制备的相应有机金属锌在Negishi交叉偶合中具有更高的反应活性。此外,使用TMPZnCl·LiCl(TMP = 2,2,6,6-四甲基哌啶基),从新戊酰氧基甲基亚砜开始,制备(新戊酰氧基甲基)氯化锌的取代衍生物,然后进行亚砜-镁交换。
  • Dual-acting antihypertensive agents
    申请人:Choi Seok-Ki
    公开号:US20080188533A1
    公开(公告)日:2008-08-07
    The invention is directed to compounds of formula I: wherein Ar, r, R 3 , X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and a process and intermediates for preparing such compounds.
    该发明涉及以下化合物的公式I:其中Ar、r、R3、X和R5-7如规范中定义,并且其药用盐。公式I的化合物具有AT1受体拮抗活性和脑利钠酶抑制活性。该发明还涉及包含这种化合物的药物组合物;使用这种化合物的方法;以及制备这种化合物的过程和中间体。
  • SUBSTITUTED IMIDAZOLES
    申请人:CHUBB NATHAN ANTHONY LOGAN
    公开号:US20080125473A1
    公开(公告)日:2008-05-29
    This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    本发明涉及一系列α取代的2-苯甲基取代咪唑化合物及其药学上可接受的盐和溶剂化物,包括含有这种化合物的组合物,它们的合成过程以及它们作为寄生虫药物的用途。
  • DUAL-ACTING ANTIHYPERTENSIVE AGENTS
    申请人:Allegretti Paul
    公开号:US20110281925A1
    公开(公告)日:2011-11-17
    The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
    该发明涉及具有以下式子的化合物:其中:Ar、r、Y、Z、Q、W、X和R5-7如规范中所定义,并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和酶解酶抑制活性。该发明还涉及包含这些化合物的制药组合物;使用这些化合物的方法;以及制备这些化合物的过程和中间体。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐